The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities
Open accessAbstract
The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Resolution of fibrosis involves not only the degradation of ECM but also reprogramming of the immune microenvironment (87, 88).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 1×
“HSC activation can be regulated by the Hippo pathway [65].”
BackgroundMechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496 · cited 1×
“PDGF belongs to a group of growth factors whose physiological functions include controlling cell proliferation and migration and promoting the synthesis of vital components of the connective tissue matrix [23,61].”
BackgroundHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485 · cited 1×
“Consequently, reducing the number of aHSCs, including inhibiting their proliferation or activation [7,24], promoting HSC apoptosis or autophagy [11,68,80], and deactivating the activated HSCs [76,77] to reverse liver fibrosis, may be an anti-fibrosis strategy [81].”
BackgroundMacrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392 · cited 1×
“Among them, hepatic macrophages (KCs), which are located within the lumen of the liver sinusoids [17], play crucial roles in liver fibrosis development [47].”
BackgroundLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“The predominant macrophage populations in the initial stages of the damage are pro-inflammatory [46].”
BackgroundLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047 · cited 1×
“Although changing the phenotype of LSECs, this imbalance also helps to activate HSCs, which in turn encourages inflammation and liver fibrosis [43,44].”
BackgroundPathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 1×
“Eliminating the chronic liver injury causes liver fibrosis to regress along with a decrease or disappearance of aHSCs [74].”
BackgroundTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Cited by
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 162
“In contrast to its advanced cirrhotic state, liver fi brosis is reversible [28, 29].”
Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
“Chronic inflammation due to persistent liver damage can induce fibrosis by disrupting the normal healing response [18].”
BackgroundLiver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives
Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., & Wadgaonkar, R. (2024) · Biomedicines · doi:10.3390/biomedicines12102229 · Cited by 70
Kidney Fibrosis: Fundamental Questions, Challenges, and Perspectives
Liu, Y. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00027 · Cited by 74
Liu, W., Zhang, L., Wei, X., Xu, Y., Fang, Q., Qi, S., Chen, J., Wang, C., Wang, S., Qin, L., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121659 · Cited by 52
Metadata
- Authors
- Pei, Q., Yi, Q., & Tang, L.
- Affiliations
- Chongqing University (CN)
- Southwest Medical University (CN)
- Corresponding author
- Yi, Qian
- Tang, Liling
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-02
- Volume
- 24
- Issue
- 11
- Pages
- 9671
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10253436
- OpenAlex
- W4379230272
- Cited by
- 121
- References
- 167
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 36 · 2023: 5
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Luzhou Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Sichuan Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, fibrosis resolution, hepatic stellate cells, hepatic stellate cell activation, extracellular matrix accumulation, liver cirrhosis, hepatocellular carcinoma, antifibrotic therapy, signaling pathways, therapeutic target, apoptosis
- MeSH terms
- Fibrosis, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities. https://app.cochat.ai/papers/10.3390/ijms24119671
- The paper
- Pei, Q., Yi, Q., & Tang, L. (2023). Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.